02.11.2018 • News

Ma’aden Awards Phosphate Contract to Daelim

Ma’aden Awards Phosphate Contract to Daelim (c) Daelim
Ma’aden Awards Phosphate Contract to Daelim (c) Daelim

Saudi Arabian Mining Company (Ma’aden) has awarded an engineering, procurement and construction (EPC) contract to South Korea’s Daelim for the first plant to be built as part of its third large-scale phosphate complex at Ras Al-Khair on Saudi Arabia’s east coast.

Daelim Industrial and Saudi Daelim will jointly perform EPC services on the plant, which will produce 1.1 million t/y of ammonia. The project will take 38 months to implement.

The complex, known as Phosphate 3, will increase Ma’aden’s phosphate capacity by 3 million t/y to a total of 9 million t/y, making the Kingdom the world’s third-largest producer of phosphate fertilizer and the second-largest exporter.

Ma’aden said the overall project, which is expected to cost $6.4 billion, will be built in stages and phased in by 2024. It will generate non-oil GDP growth of $6.7 billion and create approximately 7,000 direct and indirect jobs.

Daelim recently provided EPC services on an ammonia plant for Ma’aden Waad Al-Shamal Phosphate Company, a joint venture between Ma’aden, SABIC and US fertilizer group Mosaic. The 1.1 million t/y ammonia facility, one of seven plants at the phosphate complex that is also located at Ras Al-Khair, started commercial production in 2017.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read